SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : Trends Worth Watching
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Glenn Petersen who wrote (3323)11/28/2023 10:26:27 AM
From: Clark Kent1 Recommendation

Recommended By
Glenn Petersen

   of 3363
 
The product works.
ir.lexariabioscience.com

Lexaria's Technology Lowers Blood Glucose More Effectively than Rybelsus(R)-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study

November 28, 2023 9:10am EST Download as PDF


DehydraTECHTM-powered semaglutide achieved these benefits in a human pilot study compared to Rybelsus®:

  • Sustained lower levels of blood glucose from baseline including nearly 10x lower after 24 hours;
  • Lower blood-glucose spike after eating; and
  • Successful first-ever DehydraTECH test with a "large molecule" drug.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News